Larry Borish Selected Research

Sinusitis

10/2013	Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.
9/2013	Chronic sinusitis pathophysiology: the role of allergy.
9/2012	Etiology of nasal polyps in cystic fibrosis: not a unimodal disease.
10/2011	Genetics and phenotyping in chronic sinusitis.
2/2008	Role of hypoxia in inflammatory upper airway disease.
3/2007	Hypoxia stimulates inflammatory and fibrotic responses from nasal-polyp derived fibroblasts.
9/2006	Expression of leukotriene C4 synthase and plasminogen activator inhibitor 1 gene promoter polymorphisms in sinusitis.
6/2006	Fungi in chronic hyperplastic eosinophilic sinusitis: reasonable doubt.
11/2005	Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma.
6/2005	Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Larry Borish Research Topics

Disease

39	Asthma (Bronchial Asthma) 01/2022 - 12/2002
24	Inflammation (Inflammations) 01/2021 - 04/2002
16	Hypersensitivity (Allergy) 01/2022 - 06/2004
16	Rhinosinusitis 01/2022 - 12/2002
14	Sinusitis 10/2013 - 04/2002
13	Nasal Polyps (Nasal Polyp) 01/2022 - 11/2006
12	Eosinophilia 01/2021 - 02/2003
10	Infections 11/2022 - 09/2014
8	Allergic Rhinitis 11/2020 - 04/2002
7	Rhinitis 01/2021 - 12/2003
5	Anaphylaxis (Anaphylactic Shock) 10/2020 - 06/2004
5	Polyps 01/2016 - 03/2007
5	Fibrosis (Cirrhosis) 10/2011 - 06/2005
3	Immediate Hypersensitivity 01/2021 - 05/2013
3	Allergic Fungal Sinusitis 07/2016 - 11/2006
3	Hypoxia (Hypoxemia) 11/2008 - 03/2007
3	Bronchial Spasm 05/2008 - 05/2004
2	Chronic Urticaria 07/2018 - 07/2010
2	Agammaglobulinemia (Hypogammaglobulinemia) 01/2018 - 08/2015
2	Hyperplasia 11/2017 - 06/2005
2	Anosmia 11/2016 - 07/2016
2	Respiratory Hypersensitivity 01/2013 - 03/2002
1	COVID-19 01/2022
1	Bronchial Hyperreactivity 01/2022
1	Primary Immunodeficiency Diseases 01/2022
1	Human Influenza (Influenza) 01/2022
1	Gastroesophageal Reflux (GERD) 01/2021
1	Disease Progression 01/2020
1	Cystic Fibrosis (Mucoviscidosis) 01/2020
1	Drug Hypersensitivity (Drug Allergy) 11/2019
1	Common Variable Immunodeficiency 01/2018
1	Reinfection 01/2018
1	Cerebrospinal Fluid Rhinorrhea 01/2016
1	Meningoencephalitis 08/2015
1	Lymphopenia (Lymphocytopenia) 08/2015

Drug/Important Bio-Agent (IBA)

22	Immunoglobulin E (IgE)IBA 01/2021 - 03/2003
15	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 11/2004
13	CytokinesIBA 01/2021 - 03/2002
12	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 12/2003
11	LeukotrienesIBA 01/2021 - 04/2002
11	AllergensIBA 01/2020 - 03/2002
5	Interleukin-5 (Interleukin 5)IBA 01/2022 - 03/2002
4	AntigensIBA 11/2022 - 03/2002
4	anti-IgE antibodiesIBA 01/2021 - 05/2013
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 03/2007
4	InterleukinsIBA 11/2020 - 02/2004
4	Proteins (Proteins, Gene)FDA Link 10/2020 - 02/2008
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 11/2013
3	Antiviral Agents (Antivirals)IBA 01/2022 - 05/2008
3	Biomarkers (Surrogate Marker)IBA 12/2017 - 01/2015
3	SteroidsIBA 12/2017 - 11/2005
3	Biological ProductsIBA 01/2015 - 05/2013
3	2-(N-cyclohexylamino)ethanesulfonic acid (CHES)IBA 09/2013 - 06/2006
3	Interleukin-33IBA 01/2013 - 02/2011
3	Interleukin-4 (Interleukin 4)IBA 01/2012 - 04/2010
3	AntibodiesIBA 07/2010 - 02/2006
2	Immunoglobulin G (IgG)IBA 01/2022 - 01/2020
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2022 - 06/2005
2	ChemokinesIBA 01/2021 - 05/2004
2	Interleukin-13IBA 11/2020 - 04/2010
2	RNA (Ribonucleic Acid)IBA 10/2020 - 10/2011
2	Omalizumab (Xolair)FDA Link 01/2020 - 07/2018
2	mepolizumabIBA 01/2020 - 01/2015
2	Chemotactic FactorsIBA 01/2019 - 01/2019
2	AutoantibodiesIBA 09/2014 - 07/2010
2	SuperantigensIBA 11/2013 - 09/2013
2	Interleukin-10 (Interleukin 10)IBA 01/2013 - 09/2004
2	cysteinyl-leukotrieneIBA 10/2009 - 02/2003
2	Oxygen (Dioxygen)IBA 02/2008 - 03/2007
2	Leukotriene C4IBA 09/2006 - 11/2004
1	Immunoglobulins (Immunoglobulin)IBA 11/2022
1	Polysaccharides (Glycans)IBA 11/2022
1	EnzymesIBA 01/2021
1	Prostaglandin D2IBA 01/2021
1	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 01/2021
1	Antivenins (Antivenoms)IBA 01/2021
1	Interleukin-5 Receptors (Interleukin 5 Receptor)IBA 01/2021
1	Thymic Stromal LymphopoietinIBA 01/2021
1	Crotalidae Polyvalent immune FabIBA 01/2021
1	LipidsIBA 01/2021
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 10/2020
1	Indicators and Reagents (Reagents)IBA 10/2020
1	Immunoglobulin A (IgA)IBA 01/2020
1	Neutralizing AntibodiesIBA 01/2020
1	Dinoprostone (PGE2)FDA Link 11/2019
1	Prednisone (Sone)FDA LinkGeneric 07/2019
1	leukotriene A4 hydrolaseIBA 01/2019
1	Leukotriene B4IBA 01/2019
1	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 01/2019
1	Itraconazole (Sporanox)FDA LinkGeneric 11/2016
1	Cyclooxygenase InhibitorsIBA 11/2016
1	MucinsIBA 07/2016
1	Rituximab (Mabthera)FDA Link 08/2015
1	Monoclonal AntibodiesIBA 01/2015
1	reslizumabIBA 01/2015
1	benralizumabIBA 01/2015
1	Interferon gamma ReceptorIBA 09/2014

Therapy/Procedure

20	Therapeutics 01/2022 - 12/2003
7	Immunotherapy 01/2022 - 06/2004
1	Ambulatory Care (Outpatient Care) 11/2016